Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $47.80.

ELVN has been the subject of a number of research analyst reports. HC Wainwright boosted their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Mizuho boosted their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Finally, The Goldman Sachs Group boosted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a report on Friday.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently modified their holdings of the business. KBC Group NV bought a new stake in shares of Enliven Therapeutics in the first quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Finally, AlphaQuest LLC bought a new stake in shares of Enliven Therapeutics in the third quarter worth $96,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $39.59 on Thursday. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $48.53. The stock has a market capitalization of $2.41 billion, a P/E ratio of -23.71 and a beta of 0.32. The stock has a 50-day simple moving average of $37.48 and a 200 day simple moving average of $27.59.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Research analysts forecast that Enliven Therapeutics will post -1.7 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.